Caribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright's Robert Burns reiterated a Buy rating for Caribou Biosciences, citing strong financials and positive clinical trial results for CB-010. The company's Q3 2025 financials showed a better-than-expected net loss per share, with cash reserves projected to last until the second half of 2027. The ANTLER trial for vispa-cel (CB-010) showed efficacy comparable to FDA-approved CAR-T therapies, with improved safety. A Phase 3 trial is set to begin, supported by the FDA. Truist Financial also reiterated a Buy rating with a $7 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments